I honestly think there is some serious misinterpretation going on. Although I don't know the full ramifications of not being in stage 2 (yet?), the fact that paxalisib reached full recruitment before other treatment arms means that it is outperforming the other treatment arms. That is how the recruitment is allotted in this study.
Ann: GBM Agile Update, page-34
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)